SCTV 01E
Alternative Names: COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine -; SCTV-01ELatest Information Update: 23 Feb 2024
At a glance
- Originator Sinocelltech
- Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 09 Feb 2024 Sinocelltech withdraws a phase-II trial for COVID-2019 infections (Prevention, In volunteers) (IM, Injection), prior to enrolment as there was not a need of this trial any more (NCT05308602)
- 15 Jan 2024 Sinocelltech completes a phase II trial in COVID-2019 infections (Prevention, In adults, In children, In the elderly) in China (IM) (NCT05652543)
- 13 Jan 2023 Sinocelltech plans a phase III trial for COVID-19 infections (Prevention, In adults, In the elderly) (IM, Injection) in January 2023 (NCT05683561)